Novel Inhibitors of 2'- O-Methyltransferase of the SARS-CoV-2 Coronavirus

Molecules. 2022 Apr 23;27(9):2721. doi: 10.3390/molecules27092721.

Abstract

The COVID-19 pandemic is still affecting many people worldwide and causing a heavy burden to global health. To eliminate the disease, SARS-CoV-2, the virus responsible for the pandemic, can be targeted in several ways. One of them is to inhibit the 2'-O-methyltransferase (nsp16) enzyme that is crucial for effective translation of viral RNA and virus replication. For methylation of substrates, nsp16 utilizes S-adenosyl methionine (SAM). Binding of a small molecule in the protein site where SAM binds can disrupt the synthesis of viral proteins and, as a result, the replication of the virus. Here, we performed high-throughput docking into the SAM-binding site of nsp16 for almost 40 thousand structures, prepared for compounds from three libraries: Enamine Coronavirus Library, Enamine Nucleoside Mimetics Library, and Chemdiv Nucleoside Analogue Library. For the top scoring ligands, semi-empirical quantum-chemical calculations were performed, to better estimate protein-ligand binding enthalpy. Relying upon the calculated binding energies and predicted docking poses, we selected 21 compounds for experimental testing.

Keywords: SARS-CoV-2; docking; nsp16 inhibitor; quantum chemistry; virtual screening.

MeSH terms

  • COVID-19 Drug Treatment*
  • Humans
  • Methyltransferases / chemistry
  • Molecular Docking Simulation
  • Pandemics
  • RNA, Viral / genetics
  • S-Adenosylmethionine
  • SARS-CoV-2*
  • Viral Nonstructural Proteins / metabolism

Substances

  • RNA, Viral
  • Viral Nonstructural Proteins
  • S-Adenosylmethionine
  • Methyltransferases